MannKind Corporation announced a $50 million private placement led by Frazier Life Sciences, selling common stock and pre-funded warrants to institutional investors. The funds will support general corporate purposes, including a $45 million payment linked to the recent FDA approval of their drug Furoscix ReadyFlow™, an autoinjector for treating edema in heart failure and chronic kidney disease. The financing is expected to close around July 24, 2026, and MannKind plans to register the resale of these securities with the SEC. This capital raise aims to strengthen MannKind's position as it advances treatments for cardiometabolic and orphan lung diseases.
Circle is hiring a senior director based in South Korea to lead its efforts in expanding the USD Coin (USDC) stablecoin ecosystem in the country. The role involves planning market entry, building partnerships with local financial and digital asset fi...
A study detected over 28 million protected-flow sandwich attacks on Solana from July 2023 to June 2026, involving 8,631 bots and generating around $345 million in profit after fees. These attacks exploit private transaction systems designed to limit ...
Kazakhstan is promoting the use of flare gas to power crypto mining, aiming to revive an industry hit by power restrictions. The government allows miners to buy waste gas from oil fields, providing up to 1.3TWh of low-cost energy while reducing emiss...
Binance Wallet has introduced support for using USDT stablecoin to pay gas fees on four major blockchain networks: BNB Smart Chain, Ethereum, Solana, and Tron. Gas fees are transaction costs required to process operations on these blockchains. This u...
A three-year academic study analyzing sandwich attacks across six blockchains found Solana heavily affected with 28 million attacks. However, users of Jupiter Ultra experienced significantly fewer sandwich attacks due to its protective features like ...
